ClinicalTrials.gg
CompletedNCT04815733Updated Apr 26, 2023

Pressure Support Ventilation During Laparoscopic and Abdominal Robotic Surgery.

An interventional study of Mandatory ventilation and pressure support ventilation in Ventilator-Induced Lung Injury, sponsored by Moscow Clinical Scientific Center. Completed at 1 site in Russian Federation. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-26.

Sponsored by Moscow Clinical Scientific Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Jun 2017, registered Oct 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a single-center, blind, prospective, randomized, controlled trial of pressure support ventilation (PSVpro) versus pressure control ventilation - volume guaranteed (PCV - VG) during laparoscopic and robotic abdominal surgery.

Read the detailed description

The objective of the study to evaluate the possibility and feasibility of using PSVpro during anesthesia during long-term laparoscopic and robot-assisted abdominal operations at different levels of neuromuscular block.

Intervention: We plan to include 100 patients who will undergo elective long (more 2 hours) laparoscopic or abdominal robotic surgery. All patients will be randomly assigned in two groups in ratio 1:1. 1 group- deep neuromuscular block and mandatory ventilation; 2 group- partial neuromuscular block and pressure support ventilation.

Expected Results. PSV may reduce the systemic inflammatory response compared to the mandatory ventilation during laparoscopic and abdominal robotic surgery.

02

Conditions studied

  • Ventilator-Induced Lung Injury

Keywords

  • pressure support ventilation
  • anaesthesia
  • lung injury
  • laparoscopic surgery
03

In context

Ventilator-Induced Lung Injury

122 studies on the registry are indexed under Ventilator-Induced Lung Injury; 40 are open to participants now.

This study's enrollment of 106 is above the median of 40 across 76 interventional studies indexed under Ventilator-Induced Lung Injury.

Browse Ventilator-Induced Lung Injury studies →

Lead sponsor

Moscow Clinical Scientific Center is the lead sponsor of 13 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written consent.
  • Men and women aged 18 years or more.
  • The physical status from I, II or III.
  • \<= 34.9 kg / m2.
  • Low risk of respiratory complications.
  • Laparoscopic surgery in the pelvis.

Exclusion criteria

Exclusion criteria:

  • The physical status from .
  • > = 35 kg / m2.
  • Neuromuscular disease.
  • Allergy to Anesthetic Agents.
  • Operations on two cavities.
  • Operations on the chest cavity.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
106 participants (actual)

Study arms

  • Active comparator
    Mandatory ventilation

    deep neuromuscular block and mandatory ventilation (PCV-VG);

    Procedure: Mandatory ventilation

  • Experimental
    Pressure support ventilation

    partial neuromuscular block and pressure support ventilation (PSVpro).

    Procedure: pressure support ventilation

Interventions

  • ProcedureMandatory ventilation

    Use PCV-VG

  • Procedurepressure support ventilation

    Use PSVpro

06

What researchers measure

Primary outcomes

  1. Concentrations of biomarkers of lung injury

    Measure concentration of Interleukin-6 (IL-6), Interleukin-8 (IL-8), tumor necrosis factor receptor I / II (sTNF rI / II)) in blood serum

    Time frame: 1-3 hours after surgery

Secondary outcomes

  1. Maximum intraoperative lactate level in the early postoperative period

    Maximum intraoperative lactate level

    Time frame: 1 hour after surgery

  2. The maximum level of vasopressor support during surgery

    Norepinephrine consumption (mcg/kg/h)

    Time frame: From time of skin incision to time of skin closure assessed up to 24 hours

Other outcomes

  1. Duration of anaesthesia.

    Duration of anaesthesia.

    Time frame: Period of time from induction to volatile anesthetic supply stop assessed up to 24 hours

  2. Procedure time

    Length of ventilation

    Time frame: Period of time from intubation to extubation assessed up to 24 hours

  3. Length of stay (LOS) in the intensive care unit (ICU).

    Length of stay (LOS) in the intensive care unit (ICU).

    Time frame: Period of time from ICU arrival to discharge from ICU assessed up to 1 year

  4. Time to reach an Aldrete score > 9 points after anaesthesia

    Time to reach an Aldrete score \> 9 points after anaesthesia

    Time frame: Period of time from volatile anesthetic suplly stop to time when patient has more than 9 points according Aldrete score assessed up to 24 hours

  5. Intraoperative consumption of muscle relaxant

    mg/kg of muscle relaxant

    Time frame: Since skin incision to skin closure assessed up to 24 hours

  6. Intraoperative consumption of reversal agents.

    mg/kg of reversal agents.

    Time frame: Since skin incision to skin closure assessed up to 24 hours

  7. Supplemental oxygen in the early postoperative period

    Duration of oxygen supply

    Time frame: Since extubation up to 24 hours after extubation

  8. Quality of recovery score-40

    The QoR-40 incorporates five dimensions of health: patient support, comfort, emotions, physical independence, and pain; each item is graded on a five-point Likert scale. QoR-40 scores range from 40 (extremely poor quality of recovery) to 200 (excellent quality of recovery).

    Time frame: 24 hours after surgery

  9. Changes of spirometry parameter FVC after surgery

    FVC before surgery (L) - FVC after surgery (L)

    Time frame: 1 hour and 24 hours after surgery

  10. Changes of spirometry parameter FEV1 after surgery

    FEV1 before surgery (L)- FEV1 after surgery (L)

    Time frame: 1 hour and 24 hours after surgery

  11. Changes of spirometry parameter FEV1/FVC after surgery

    FEV1/FVC before surgery (percentage %) - FEV1/FVC after surgery (percentage %)

    Time frame: 1 hour and 24 hours after surgery

  12. Changes of spirometry parameter PEF after surgery

    PEF before surgery (L/s) - PEF after surgery (L/s)

    Time frame: 1 hour and 24 hours after surgery

  13. Changes of spirometry parameter VC after surgery

    VC before surgery (L) - VC after surgery (L)

    Time frame: 1 hour and 24 hours after surgery

  14. Changes of spirometry parameter FEV1/VC after surgery

    FEV1/VC before surgery (percentage %) - FEV1/VC after surgery (percentage %)

    Time frame: 1 hour and 24 hours after surgery

  15. Volume of atelectasis of lungs after surgery

    Volume of the lungs measure according to CT lung The volume of atelectasis is the difference in volumes of lungs before and after surgery

    Time frame: 24 hours after surgery

  16. The level of pain assess after surgery by Numeric Rating Scale (NRS)

    No pain - 0, worst pain - 10

    Time frame: 1 hour after surgery

  17. The level of pain assess after surgery by Numeric Rating Scale (NRS)

    No pain - 0, worst pain - 10

    Time frame: 3 hours after surgery

  18. The level of pain assess after surgery by Numeric Rating Scale (NRS)

    No pain - 0, worst pain - 10

    Time frame: 24 hours after surgery

  19. Length of stay (LOS) in hospital

    Length of stay (LOS) in hospital

    Time frame: 28 days

07

Study locations

1 site
  • Moscow Clinical Scientific Center
    Moscow, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Mar 2023, 69 months.

Of 40 interventional studies with no phase under Ventilator-Induced Lung Injury, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 53. This study's 69 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2020
First posted
Mar 25, 2021
StartActual
Jun 1, 2017
Primary completionActual
Mar 31, 2023
CompletionActual
Mar 31, 2023
Last update
Apr 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04815733
Lead sponsor
Moscow Clinical Scientific Center
Responsible party
Valerii Subbotin (PhD, Moscow Clinical Scientific Center) — Principal investigator
First posted
Mar 25, 2021
Start date
Jun 1, 2017
Primary completion
Mar 31, 2023
Completion
Mar 31, 2023
Last update
Apr 26, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion